Notably, we have become increasingly focused on targets that suggest high efficacy and low competition, as well as oncology indications where there is a high and undisputable unmet medical need.
However, we continue to be impressed by the progression of the underlying science and higher-than-average odds of clinical success for such programs. Notably, we have become increasingly focused on targets that suggest high efficacy and low competition, as well as oncology indications where there is a high and undisputable unmet medical need. In our view, innovations with these characteristics are better positioned to navigate the evolving challenges in the precision oncology space.